Hi, what are you looking for?
Jewish Business News
Search results for " Erez Vigodman"
Money
The former president and CEO Teva Americas Generics earned $7.3 million in 2014.
Court
The ruling means Teva’s flagship multiple sclerosis treatment’s patent remains valid until September 2015. The US Supreme Court has ruled in favor of...
Business
Bloomberg reports that increased competition with cheaper generics may push Teva to make a major acquisition soon. Perrigo Company (NYSE:PRGO; TASE:PRGO) may be a...
Business
Here is our list of the ten companies that made the biggest or at least the most headlines this past year, for good...
Business
– Generic competition for Copaxone and foreign currency volatility will hit Teva’s sales. – When Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA)...
Business
– The decision gives Teva more time to transfer patients to its better patent protected double dosage Copaxone. – Teva Pharmaceutical Industries Ltd. (NYSE:...
Leadership & A-List
– Teva Pharmaceutical Industries Ltd. ((NYSE: TEVA; TASE: TEVA) today announced that the Board of Directors has elected Professor Yitzhak Peterburg as Chairman, effective January 1,...
Business
– Multiple sclerosis treatment Copaxone accounts for an estimated half of Teva’s profit. – Changes in the multiple sclerosis treatment market, in which...
Business
– Sales of the multiple sclerosis treatment were down 12% in the second quarter. – Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) reported...
Business
– Barclays analyst Douglas Tsao sees the success of double-dose Copaxone as a platform for expansion. – “The mergers and acquisition phenomenon is one...